Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center, Open Clinical Study on the Efficacy and Safety of c-Met/PD-L1 Chimeric Antigen Receptor T Cell Injection in the Treatment of Primary Hepatocellular Carcinoma

NCT03672305 is registered in ClinicalTrials.gov with The Second Hospital of Nanjing Medical University as lead sponsor.

NCT NCT03672305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03672305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center, Open Clinical Study on the Efficacy and Safety of c-Met/PD-L1 Chimeric Antigen Receptor T Cell Injection in the Treatment of Primary Hepatocellular Carcinoma
Lead sponsor
The Second Hospital of Nanjing Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2018
Completion date
October 30, 2019
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary hepatocellular carcinoma